BHV BHV
Company Profile ↓Company Overview
BHV (BHV) is a publicly traded company listed on with a market capitalization of $18.20M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Maintains a net profit margin of 75.3%.
Carries low leverage with a debt-to-equity ratio of 0.01.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -22.7%, profit CAGR -30.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -22.65% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -30.85% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +6.47% |
| 6 Months: | +5.89% |
| 3 Months: | -6.54% |
| 1 Month: | -8.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 75.3%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -22.7% CAGR over 5 years.
- Earnings shrank at -30.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|
| Revenue | 1.53M | -683.94K | 917.17K | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 89.07K | 127.69K | 133.39K | - |
| Operating Income | - | - | - | - |
| EBITDA | - | - | - | - |
| Interest Expense | 158.39K | 489.67K | 524.21K | - |
| Pretax Income | 1.44M | -811.63K | 690.48K | - |
| Tax Provision | - | - | - | - |
| Net Income | 1.44M | -811.63K | 690.48K | - |
| Diluted EPS | 0.90 | -0.50 | - | -0.95 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 |
|---|---|---|---|
| Total Assets | 41.90M | 34.65M | 31.51M |
| Current Assets | - | - | - |
| Cash & Equivalents | - | - | - |
| Inventory | - | - | - |
| Receivables | 376.08K | 280.34K | 289.87K |
| Total Liabilities | 16.57M | 14.69M | 11.70M |
| Current Liabilities | - | - | - |
| Long Term Debt | - | - | - |
| Total Debt | - | 2.31K | 1.70K |
| Total Equity | 25.33M | 19.96M | 19.82M |
| Shares Outstanding | 1.61M | 1.60M | 1.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 |
|---|---|---|---|
| Operating Cash Flow | 868.06K | 1.72M | 2.78M |
| Investing Cash Flow | - | - | - |
| Financing Cash Flow | -868.06K | -1.76M | -2.77M |
| Capital Expenditure | - | - | - |
| Free Cash Flow | 868.06K | 1.72M | 2.78M |
| Net Change in Cash | 0 | -39.00K | 18.00K |
Ratios (Annual)
Figures in %.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | 94.2% | 118.7% | 75.3% | - |
| ROE % | 5.7% | -4.1% | 3.5% | - |
| ROCE % | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHV
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBFX0d6VWM1ZVNkZ3ZYVV91cTdhU3NXMy1GX3NwSEFQWVgzbUNlSWlyQUppYVU5dk5YeTV5Z3ZobVZ1RFpNbUFzSzJtN1RIdXA1TFE?oc=5" target="_blank">Biohaven Ltd. (BHVN) stock price, news, quote and histor…
Liquidity Mapping Around (BHV) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQVlByQ2ZBTXF0cEtPd3NDZE5tcjZjbEcyYVRmRDZnRzhrVTgtWDFLLUZ3X0ZXdE5yMXRPTFBuMWVmVTBIMFF1STc3N2NRdjZFN2QtUFE0YVp4WkxuV01rZWpGWkRXbEVZb1JSM2paeEh4SlZMNzdpeDJWdFFIUFczalhkT0J6ZFBsUXVPOU…
Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera Lead Immunology Asset - Pharmaceutical Executive
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPczNTY0xwVmk3QUpnb0xLQkJnUXhZNW5Dc1VVeVUyMXJQckhKVHdHVDJ4QkljSkgwV1lxR3pKT3RKTkJZaWNySUlNNWJtd3FnMEs5Q3I4Mko1SXF4ZVpIcmQ2ZDlmOUVCT0pmb0pzVkxDX2VCMmtWZEliU19ZanF6WUo0Y24yZlJNSU9zSG…
BHVN Stock Pops As Ono Deal Delivers Cash And Validation - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE52RllhN0hIVEJrSVZyRGpjSVpXMDA5c2JqTWpSY0dLUGpkdXBWNTJyQ0VhdnhaVHRFQjFGbXhPQ3lVd0RmLWpPZnZGdGYwY3RfSHlMZmxwRmc0VzlFNVdOZU8zcFdVUlZDaWxtUjNQXzhoSWc?oc=5" target="_blank">BHVN Stock P…
Biohaven's cancer drug produced tumor shrinkage in heavily pretreated patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeXZfUEJXYVZ2cmZkOVIzNWRZS3hNTGhtQWpFbnRmd2swNzhkYU0wc2FCQ1ZWWlNwN1pnZmxXdDUyTUc4eXBlS1NNZ0lkVUJFNTRKTEo3STlaYjdVTVJFT2lnSTZCNWpycXNUMXlOVmFNYmpNNjlwcVZ2NVd3VzhlOXZ1RTRBd1M5Zlc3eW…
Biohaven - Despite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPcTBQb1k3THk4UHRWVFllVTNGRW1SWWNvNHRONkxXWEN1X2liY0dmQTVIc3BWTjB3YUxINjJhN3hud0FZYzI3X2JlcjZJWkVsTXZoenFQcEFhNXExSlg3bXlqNkR6NGJHZVVMWlpmVkNEV0Z1TlNRYmlSZkJCQlpfb1dKNVlnUFB3Ukk2ZU…
BHV — Frequently Asked Questions
What is the current share price of BHV?
As of 2026-10-23 16:27 PDT, BHV trades at $11.46 on NASDAQ/NYSE. Its 52-week range is $9.93 to $13.05.
What is the market capitalisation of BHV?
BHV has a market capitalisation of $18.20M on NASDAQ/NYSE.
What is the P/E ratio of BHV?
BHV trades at a trailing price-to-earnings (P/E) ratio of -12.06. Its price-to-book (P/B) ratio is 0.92.
What is the return on equity (ROE) of BHV?
BHV has a return on equity (ROE) of 3.48%.
Is BHV a good stock to buy?
This page provides a data-driven analysis of BHV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.